ClinicalTrials.gg
CompletedNCT01407068Updated Oct 5, 2017Results posted

Administration of Two Injections for Multiple Dupuytren's Contractures

A Phase 3 interventional study of AA4500 collagenase clostridium histolyticum in Dupuytren's Contracture, sponsored by Endo Pharmaceuticals. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.

Enrollment
10th of 17
60 · median 76
Started
2011
with 1 other
Phase 3
7 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
6 of 17
Endo Pharmaceuticals

Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 10th largest by enrollment, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 7th registered.

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

Browse Dupuytren Contracture studies →

Open to participants now

None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Microbial Collagenase in Dupuytren Contracture as a file.
02

Study summary

The objectives of this study are to assess the safety and efficacy of concurrent administration of two injections of AA4500 into the same hand of subjects with multiple Dupuytren's contractures caused by palpable cords.

Read the detailed description

Methodology/Study Design:

This is an open-label, study in men and women with multiple Dupuytren's contractures. Approximately 60 subjects who have at least two Dupuytren's contractures caused by palpable cords in the same hand will be enrolled.

After all pre-injection procedures are completed on Day 1, eligible men and women will receive two concurrent injections of AA4500 0.58 mg into the same hand. On Day 2, a finger extension procedure to facilitate cord disruption will be performed in those subjects who do not have spontaneous disruption of their cord(s). Follow-up visits for the evaluation of safety and efficacy will be on Day 8, Day 30, and Day 60.

Upon completion of the Day 60 follow-up visit, subjects who require further treatment will have the option to receive three additional open-label treatments according to the XIAFLEX package insert (Appendix C). Subjects may receive up to a total of five injections and individual cords may receive up to a total of three injections.

03

Conditions studied

  • Dupuytren's Contracture

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written
  2. Be a man or woman ≥ 18 years of age
  3. Have a diagnosis of Dupuytren's disease and have at least 2 fixed-flexion contractures on the same hand that are ≥ 20º in PIP and/or MP joints in fingers, other than the thumbs, which are caused by palpable cords suitable for treatment
  4. Have a positive "table top test" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top
  5. Either be using an accepted method of (ie, surgical sterilization; intra uterine contraceptive device; oral contraceptive; diaphragm or condom in combination with contraceptive cream, or jelly or foam) and have negative pregnancy testing before administration of AA4500, if a female of , or be a female (no menses for at least 1 year or hysterectomy)
  6. Not have any medical history or condition(s) that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
  7. Be able to comply with the study visit schedule as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Received surgery (fasciectomy or surgical fasciotomy) and/or needle aponeurotomy/fasciotomy on the selected joints to be treated within 90 days before the first injection of AA4500
  2. Has a chronic muscular, neurological, or neuromuscular disorder that affects the hands
  3. Has a known systemic allergy to collagenase or any other of AA4500
  4. Has received any collagenase treatments (eg, Santyl® ointment and/or XIAFLEX/XIAPEX) within 30 days before injection of AA4500
  5. Is currently receiving or plans to receive anticoagulant medication or has received anticoagulant medication (except for ≤ 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory drugs [NSAIDs]) within 7 days before injection of AA4500)
  6. Has a known recent history of stroke, bleeding, or other medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study
  7. Is known to be or (HIV) positive
  8. Has a history of illicit drug abuse or alcoholism within the year before injection of AA4500
  9. Received an drug within 30 days before injection of AA4500
  10. Is a pregnant or lactating female
  11. Has any medical history or condition(s), including conditions that affect the hands, that would, in the opinion of the investigator, substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives of the study
  12. Has jewelry on the hand to be treated that cannot be removed
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    AA4500

    AA4500 collagenase clostridium histolyticum

    Biological: AA4500 collagenase clostridium histolyticum

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Fixed Flexion

    Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment. Change in fixed-flexion contracture is measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees

    Time frame: 30 days after last injection

  2. Change in Total Range of Motion

    The total range of motion is the sum of the range of motion measurements of the two treated joints. Range of motion is defined as difference between full flexion angle and full extension angle expressed in degrees.

    Time frame: 30 days after last injection

Secondary outcomes

  1. Subject Satisfaction With Treatment

    At the Day 60 follow-up visit, each subject will be asked to rate his/her satisfaction with treatment as follows: 1. Very Satisfied 2. Quite Satisfied 3. Neither Satisfied nor Dissatisfied 4. Quite Dissatisfied 5. Very Dissatisfied

    Time frame: 60 days after last injection

  2. Investigator Assessment of Improvement With Treatment

    At the Day 60 follow-up visit, the investigator will determine the degree of improvement in the severity of the subject's treated finger(s) compared with screening as follows: 1. Very Much Improved 2. Much improved 3. Minimally Improved 4. No Change 5. Minimally Worse 6. Much Worse 7. Very Much Worse

    Time frame: 60 days after last injection

  3. Clinical Success by Joint Type

    Clinical success is defined as a reduction in fixed flexion contracture to 5° or less 30 days after injection of AA4500.

    Time frame: 30 days after injection

07

Results

Posted Feb 20, 2015

Participant flow

Participant flow — Overall Study
MilestoneAA4500
Started60
Completed60
Not completed0

Outcome measures

PrimaryPercent Change From Baseline in Total Fixed Flexion

Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment. Change in fixed-flexion contracture is measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees

Time frame:
30 days after last injection
Reported as:
Mean · percentage of contracture change
Percent Change From Baseline in Total Fixed Flexion
percentage of contracture changeAA4500
Percent Change From Baseline in Total Fixed Flexion75.5 ± 24.11
SecondarySubject Satisfaction With Treatment

At the Day 60 follow-up visit, each subject will be asked to rate his/her satisfaction with treatment as follows: 1. Very Satisfied 2. Quite Satisfied 3. Neither Satisfied nor Dissatisfied 4. Quite Dissatisfied 5. Very Dissatisfied

Time frame:
60 days after last injection
Reported as:
Number · participants
Subject Satisfaction With Treatment
participantsAA4500
Very satisfied36
Quite satisfied17
Neither satisfied nor dissatisfied5
Quite dissatisfied1
Very dissatisfied1
Not done0
SecondaryInvestigator Assessment of Improvement With Treatment

At the Day 60 follow-up visit, the investigator will determine the degree of improvement in the severity of the subject's treated finger(s) compared with screening as follows: 1. Very Much Improved 2. Much improved 3. Minimally Improved 4. No Change 5. Minimally Worse 6. Much Worse 7. Very Much Worse

Time frame:
60 days after last injection
Reported as:
Number · participants
Investigator Assessment of Improvement With Treatment
participantsAA4500
Very much improved33
Much improved22
Minimally improved4
No change1
Minimally worse0
Much worse0
Very much worse0
Not done0
PrimaryChange in Total Range of Motion

The total range of motion is the sum of the range of motion measurements of the two treated joints. Range of motion is defined as difference between full flexion angle and full extension angle expressed in degrees.

Time frame:
30 days after last injection
Reported as:
Mean · degrees
Change in Total Range of Motion
degreesAA4500
Change in Total Range of Motion60.4 ± 21.80
SecondaryClinical Success by Joint Type

Clinical success is defined as a reduction in fixed flexion contracture to 5° or less 30 days after injection of AA4500.

Time frame:
30 days after injection
Reported as:
Number · number of joints
Clinical Success by Joint Type
number of jointsAA4500 MPAA4500 PIP
Yes5715
No1830

Adverse events

Collected over 60 days after injection. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500—3/60 (5%)60/60 (100%)
Most frequent serious events
Most frequent serious events
EventAA4500
Pain in extremityMusculoskeletal and connective tissue disorders1/60
TendonitisInjury, poisoning and procedural complications1/60
Tendon ruptureInjury, poisoning and procedural complications1/60
Ligament injuryInjury, poisoning and procedural complications1/60
Most frequent other events
Most frequent other events
EventAA4500
oedema peripheralGeneral disorders49/60
Pain in extremityMusculoskeletal and connective tissue disorders49/60
ContusionInjury, poisoning and procedural complications48/60
LymphadenopathyBlood and lymphatic system disorders22/60
PruritusSkin and subcutaneous tissue disorders20/60
Skin lacerationInjury, poisoning and procedural complications15/60
Injection site haematomaGeneral disorders11/60
Injection site swellingGeneral disorders8/60
Blood blisterSkin and subcutaneous tissue disorders7/60
EcchymosisSkin and subcutaneous tissue disorders3/60

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500
<=18 years0
Between 18 and 65 years29
>=65 years31
Age, Continuous
Age, Continuous(years)AA4500
Mean63.7 ± 10.59
Sex: Female, Male
Sex: Female, Male(Participants)AA4500
Female9
Male51
Region of Enrollment
Region of Enrollment(participants)AA4500
United States21
Australia39
08

Study locations

8 sites
  • Tucson Orthopaedic Institute
    Tucson, Arizona 85712, United States
  • The Indiana Hand Center
    Indianapolis, Indiana 46260, United States
  • Department of Orthopaedics SUNY-Stony Brook
    Stony Brook, New York 11794, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • AusTrials
    Auchenflower, QLD 4067, Australia
  • AusTrials
    Auchenflower, QLD4066, Australia
  • AusTrials
    Kippa Ring, QLD 4020, Australia
  • Emeritus Research
    Malvern, VIC 3144, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2011
First posted
Aug 1, 2011
Start
Sep 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Feb 20, 2015
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01407068
Responsible party
Sponsor
First posted
Aug 1, 2011
Start date
Sep 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Feb 20, 2015
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD, MPPH
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion